Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFlexS: Paliperidone ER in Schizophrenia
NCT00460512Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, open-label, single-arm trial of paliperidone in schizophrenia, sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of Participants With at Least 20 Percent Improvement in Total Positive and Negative Syndrome Scale (PANSS) Score at 26 weeks and Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 26 weeks. Started Apr 2007; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00460512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00460512.